GENERICS (U.K.) LIMITED

Financial Health Score: B+

Explanation: The patient exhibits excellent regulatory and compliance vitals, with no symptoms of administrative distress. As a wholly-owned subsidiary of a major global pharmaceutical parent (Mylan Group Bv, now part of Viatris), the company benefits from a robust corporate "immune system." However, the specific financial "blood work" (detailed balance sheet and profit & loss metrics) is currently restricted from view, preventing a perfect bill of health. The score reflects strong structural health based on available indicators, while acknowledging the need for deeper financial transparency to assess internal vitality.

Key Vital Signs

• Corporate Longevity (Incorporation Date: 1981): This is a mature patient. Having been incorporated for over 40 years, the business has survived numerous economic cycles, indicating deep-rooted resilience and an established market presence in the pharmaceutical sector.
• Regulatory Pulse (Filing Compliance): The company's heartbeat is strong and rhythmic. Accounts are filed up to date (December 2024), the confirmation statement is current, and there are no overdue documents. This shows excellent administrative hygiene and a low risk of regulatory infection (penalties or strike-off).
• Parental Immunity (PSC - Mylan Group Bv): The company is wholly owned (more than 75% shares and voting rights) by Mylan Group Bv. This acts as a massive financial backstop. If the UK entity experiences short-term cash flow sickness, the parent company can easily provide a financial transfusion via intercompany loans.
• Share Capital (£52,700): A stable baseline, but relatively modest for a pharmaceutical manufacturer. This suggests the company likely relies on parent company funding or retained earnings rather than a large initial share capital injection to finance its operations.
• Missing Vitals (Financial Metrics): Crucial diagnostic metrics—such as fixed assets, current assets, net current assets (working capital), and net assets—are absent from the current chart. Without these, we cannot measure the company's financial blood pressure (liquidity) or cholesterol (solvency).

Diagnosis

Based on the observable symptoms and corporate DNA, Generics (U.K.) Limited is a healthy, well-maintained subsidiary operating within a larger global pharmaceutical anatomy.

There are absolutely no symptoms of distress: no overdue filings, no director disqualifications, and no signs of insolvency. The change in name from Hackremco (No.59) Limited shortly after incorporation in 1982 is a standard procedural "birthmark" from a bygone era of UK company formations, and the current leadership, including a dedicated Finance Director and Commercial Head, indicates professional, ongoing management.

However, because the company files "Full" accounts but the detailed financial figures are not available in this dataset, we must rely on a physical examination of the exterior rather than a full blood panel. As a subsidiary of Mylan Group Bv (which operates under the Viatris umbrella following a merger), the UK entity's financial health is intrinsically tied to the parent's strategic decisions. It may be operating as a lean, asset-light distribution hub, or it may hold significant local property and inventory. Without the P&L reserve and net asset figures, we cannot definitively diagnose the internal financial muscle.

Recommendations

1. Request the Full Blood Panel: To move from a general check-up to a precise diagnosis, obtain the full, filed accounts from Companies House. You need to review the net current assets and net assets to ensure the company isn't relying too heavily on parent company "transfusions" (intercompany debt) that could suddenly be called in.
2. Monitor Intercompany Vital Signs: Because the PSC owns more than 75% of the company, pay close attention to intercompany balances in the full accounts. Healthy intercompany loans are normal, but if current liabilities are heavily skewed toward the parent company, the UK entity could be highly leveraged.
3. Maintain Regulatory Hygiene: The company has an excellent track record of staying current with Companies House. Continue this strict diet of timely filings to avoid unnecessary fines and maintain a clean public record, which is essential for a pharmaceutical manufacturer subject to high regulatory scrutiny.
4. Review Transfer Pricing Health: Given the global nature of the parent company, ensure that all transactions between the UK entity and its overseas affiliates are conducted at arm's length. This keeps the company safe from tax-related infections and HMRC inquiries.